Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019 Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-501 and Use of ALLO-647 for Lymphodepletion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Recent Highlights Include a Successful IPO, Clearance

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today

State-of-the-Art Manufacturing Facility to be Located in the San Francisco East Bay Area Allogene Committed to Advanced Cell Manufacturing for Long-Term Clinical and Commercial AlloCAR T™ Production   SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at four investor

Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma ALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion Regimen   SOUTH SAN FRANCISCO, Calif. and PARIS, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Allogene